Technical Analysis for ICPT - Intercept Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
F 21.68 0.09% 0.02
ICPT closed up 0.09 percent on Monday, March 1, 2021, on approximately normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical ICPT trend table...

Date Alert Name Type % Chg
Calm After Storm Range Contraction 0.00%
Lower Bollinger Band Walk Weakness 0.00%
New 52 Week Low Weakness 0.00%
Wide Bands Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish 0.09%
Lower Bollinger Band Walk Weakness 0.09%
New 52 Week Low Weakness 0.09%
Older End-of-Day Signals for ICPT ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Fell Below Previous Day's Low about 5 hours ago
New 52 Week Low about 5 hours ago
60 Minute Opening Range Breakdown about 5 hours ago
Rose Above Lower Bollinger Band about 10 hours ago
Up 3% about 10 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Intercept Pharmaceuticals, Inc. Description

Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat chronic liver diseases utilizing proprietary bile acid chemistry. It primarily develops obeticholic acid, a bile acid analog and farnesoid X receptor (FXR) agonist that is in Phase III clinical trials for the treatment of primary biliary cirrhosis; in Phase IIa clinical trials to treat portal hypertension; in Phase IIb clinical trials for the nonalcoholic steatohepatitis treatment; and in Phase IIa trials for the treatment of bile acid diarrhea. The company is also developing INT-767, an orally administered FXR and TGR5 agonist, which is in preclinical studies to treat fibrosis; and INT-777, an orally administered TGR5 agonist that has completed preclinical studies for the treatment of type 2 diabetes. It has strategic collaborations and research agreements with Dainippon Sumitomo Pharma Co. Ltd. and TES Pharma Srl. The company was founded in 2002 and is headquartered in New York, New York. Intercept Pharmaceuticals, Inc. is a subsidiary of Genextra S.p.A.


Sector: Healthcare
Industry: Biotechnology
Keywords: Acid Alcohol Diabetes Hypertension Gastroenterology Steatohepatitis Liver Disease Hepatology Diarrhea Fibrosis Liver Diseases Bile Acid Digestive Diseases Chronic Liver Disease Chronic Liver Diseases Cirrhosis Primary Biliary Cholangitis Farnesoid X Receptor Fxr Obeticholic Acid

Is ICPT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 98.03
52 Week Low 21.45
Average Volume 1,121,757
200-Day Moving Average 44.15
50-Day Moving Average 30.29
20-Day Moving Average 31.35
10-Day Moving Average 27.84
Average True Range 2.38
ADX 32.09
+DI 8.98
-DI 35.74
Chandelier Exit (Long, 3 ATRs ) 31.28
Chandelier Exit (Short, 3 ATRs ) 28.60
Upper Bollinger Band 40.68
Lower Bollinger Band 22.02
Percent B (%b) -0.02
BandWidth 59.50
MACD Line -2.28
MACD Signal Line -0.90
MACD Histogram -1.3838
Fundamentals Value
Market Cap 715.28 Million
Num Shares 33 Million
EPS -10.44
Price-to-Earnings (P/E) Ratio -2.08
Price-to-Sales 3.90
Price-to-Book 44.19
PEG Ratio -0.69
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 23.48
Resistance 3 (R3) 23.60 23.13 23.18
Resistance 2 (R2) 23.13 22.67 23.07 23.08
Resistance 1 (R1) 22.40 22.39 22.17 22.28 22.98
Pivot Point 21.93 21.93 21.81 21.87 21.93
Support 1 (S1) 21.20 21.47 20.97 21.08 20.38
Support 2 (S2) 20.73 21.19 20.67 20.28
Support 3 (S3) 20.00 20.73 20.18
Support 4 (S4) 19.88